Highlights ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse Other stock markets 04:00:02 2024-06-03 pm EDT			5-day change	1st Jan Change
3.31 ^USD	-3.50%		-10.05%	+99.40%

May. 30	Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating	MT
May. 07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	May. 06	MT
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell	May. 06	MT
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial	May. 06	MT
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	May. 06	CI
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	Apr. 04	MT
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ADC Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ADC Therapeutics Regains Compliance With NYSE Continued Listing Standards	Jan. 04	MT
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)	23-08-30	CI
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
ADC Therapeutics, Overland Pharmaceuticals Joint Venture Says Chinese Regulator Granted Lymphoma Drug Candidate Priority Review	23-07-24	MT
China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	23-07-24	CI
ADC Therapeutics Plans to End Phase 2 Trial of Zynlonta, Rituximab in Untreated DLBCL Patients	23-07-20	MT
ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA	23-07-11	CI
ADC Therapeutics Halts Patient Enrollment in Phase 2 Trial of Blood Cancer Treatment	23-07-11	MT
ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL	23-06-09	CI
ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress	23-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ADC Therapeutics SA

Equities

ADCT

CH0499880968

Highlights

Filters